Multimodality imaging of Alzheimer disease and other neurodegenerative dementias

Journal of Nuclear Medicine

Volumn 55, Issue 12, 2014, Pages 2003-2011

  Nasrallah, Ilya M ^a   Wolk, David A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer disease; Amyloid PET; FDG PET; MRI; Neurodegeneration

Indexed keywords

FLORBETABEN; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; FLUTEMETAMOL F 18;

AGING; ALZHEIMER DISEASE; BRAIN METABOLISM; CAUDATE NUCLEUS; CELL DENSITY; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; EARLY DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREFRONTAL CORTEX; REVIEW; SENSITIVITY AND SPECIFICITY; SENSORIMOTOR CORTEX; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL CORTEX; THALAMUS; AGED; MULTIMODAL IMAGING; NEURODEGENERATIVE DISEASES; PATHOLOGY; PROCEDURES; RADIOGRAPHY; SCINTISCANNING;

AGED; AGING; ALZHEIMER DISEASE; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; MULTIMODAL IMAGING; NEURODEGENERATIVE DISEASES; NEUROIMAGING;

EID: 84915786200     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.141416     Document Type: Review

References (85)

1. Fox C, Lafortune L, Boustani M, Dening T, Rait G, Brayne C. Screening for dementia: is it a no brainer? Int J Clin Pract. 2013;67:1076-1080.
2. World Alzheimer report 2011: the benefits of early diagnosis and intervention. http://www.alz.co.uk/research/world-report-2011. Accessed November 4, 2014.
3. Josephs KA. Frontotemporal dementia and related disorders: deciphering the enigma. Ann Neurol. 2008;64:4-14.
4. Herholz K. Perfusion SPECTand FDG-PET. Int Psychogeriatrics. 2011;23(suppl 2): S25-S31.
5. 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49:390-398.
6. Panegyres PK, Rogers JM, McCarthy M, Campbell A,Wu J. Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study. BMC Neurol. 2009;9:41.
7. Mason NS, Mathis CA, Klunk WE. Positron emission tomography radioligands for in vivo imaging of Aβ plaques. J Labelled Comp Radiopharm. 2013;56:89-95.
8. Landau SM, Breault C, Joshi AD, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70-77.
9. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012;11:669-678.
10. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013;34:457-468.
11. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302-316.
12. Davatzikos C, Xu F, An Y, Fan Y, Resnick SM. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain. 2009;132:2026-2035.
13. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007; 130:2616-2635.
14. Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77:2034-2042.
15. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. One-year brain atrophy evident in healthy aging. J Neurosci. 2009;29:15223-15231.
16. Nosheny RL, Insel PS, Truran D, et al. Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiol Aging. August 1, 2014 [Epub ahead of print].
17. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275-1283.
18. Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease: the challenges ahead. Nat Rev Neurol. 2013;9:54-58.
19. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
20. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279.
21. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-292.
22. Shi F, Liu B, Zhou Y, Yu C, Jiang T. Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer's disease: meta-analyses of MRI studies. Hippocampus. 2009;19:1055-1064.
23. Yushkevich PA, Pluta JB, Wang H, et al. Automated volumetry and regional thickness analysis of hippocampal subfields and medial temporal cortical structures in mild cognitive impairment. Hum Brain Mapp. September 2, 2014 [Epub ahead of print].
24. Da X, Toledo JB, Zee J, et al. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin. 2014;4:164-173.
25. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85-94.
26. Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging. 2012;33:198 e1-e14.
27. Dukart J, Mueller K, Villringer A, et al. Relationship between imaging biomarkers, age, progression and symptom severity in Alzheimer's disease. Neuroimage Clin. 2013;3:84-94.
28. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-216.
29. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104-1113.
30. Teune LK, Bartels AL, de Jong BM, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010;25:2395-2404.
31. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69:871-877.
32. Laforce R Jr, Buteau JP, Paquet N, Verret L, Houde M, Bouchard RW. The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: a retrospective memory clinic study. Am J Alzheimers Dis Other Demen. 2010; 25:324-332.
33. Vandenberghe R, Adamczuk K, Dupont P, Laere KV, Chetelat G. Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer's disease. Neuroimage Clin. 2013;2:497-511.
34. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65:557-568.
35. Jack CR Jr,Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133:3336-3348.
36. Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA. Early-versus late-onset Alzheimer's disease: more than age alone. J Alzheimers Dis. 2010;19:1401-1408.
37. Wolk DA. Amyloid imaging in atypical presentations of Alzheimer's disease. Curr Neurol Neurosci Rep. 2013;13:412.
38. Migliaccio R, Agosta F, Rascovsky K, et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology. 2009;73:1571-1578.
39. Wolk DA, Price JC, Madeira C, et al. Amyloid imaging in dementias with atypical presentation. Alzheimers Dement. 2012;8:389-398.
40. Pereira JM, Williams GB, Acosta-Cabronero J, et al. Atrophy patterns in histologic vs clinical groupings of frontotemporal lobar degeneration. Neurology. 2009;72:1653-1660.
41. Lindberg O, Ostberg P, Zandbelt BB, et al. Cortical morphometric subclassification of frontotemporal lobar degeneration. AJNR. 2009;30:1233-1239.
42. Rohrer JD, Geser F, Zhou J, et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology. 2010;75:2204-2211.
43. 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med. 2005;46:233-239.
44. Nestor PJ, Fryer TD, Hodges JR. Declarative memory impairments in Alzheimer's disease and semantic dementia. Neuroimage. 2006;30:1010-1020.
45. 18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration. Eur Arch Psychiatry Clin Neurosci. 2011;261:433-446.
46. 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210-1217.
47. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205-1212.
48. Kitagaki H, Hirono N, Ishii K, Mori E. Corticobasal degeneration: evaluation of cortical atrophy by means of hemispheric surface display generated with MR images. Radiology. 2000;216:31-38.
49. Wadia PM, Lang AE. The many faces of corticobasal degeneration. Parkinsonism Relat Disord. 2007;13(suppl 3):S336-S340.
50. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9:417-423.
51. 11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79:1331-1338.
52. Whitwell JL, Weigand SD, Shiung MM, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain. 2007;130:708-719.
53. 18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol. 2005;191 (suppl 1):S95-S103.
54. Papathanasiou ND, Boutsiadis A, Dickson J, Bomanji JB. Diagnostic accuracy of [I-123]-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord. 2012;18:225-229.
55. Du AT, Schuff N, Kramer JH, et al. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. Brain. 2007;130: 1159-1166.
56. Rohrer JD, Warren JD, Modat M, et al. Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology. 2009;72: 1562-1569.
57. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358-365.
58. 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol. 1983;40:711-714.
59. Tripathi M, Tripathi M, Damle N, et al. Differential diagnosis of neurodegenerative dementias using metabolic phenotypes on F-18 FDG PET/CT. Neuroradiol J. 2014;27:13-21.
60. Perani D, Schillaci O, Padovani A, et al. A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. BioMed Res Int. 2014;2014:785039.
61. Matias-Guiu JA, Cabrera-Martin MN, Garcia-Ramos R, et al. Evaluation of the new consensus criteria for the diagnosis of primary progressive aphasia using fluorodeoxyglucose positron emission tomography. Dement Geriatr Cogn Disord. 2014;38:147-152.
62. Prins ND, van der Flier WM, Brashear HR, et al. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. J Alzheimers Dis. 2013;36:79-85.
63. Prestia A, Caroli A, Herholz K, et al. Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimers Dement. 2013;9:677-686.
64. Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397-1403.
65. Jack CR Jr, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65:1227-1231.
66. Nestor SM, Rupsingh R, Borrie M, et al. Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain. 2008;131:2443-2454.
67. Josephs KA Jr, Whitwell JL, Weigand SD, et al. Predicting functional decline in behavioural variant frontotemporal dementia. Brain. 2011;134:432-448.
68. Nedelska Z, Ferman TJ, Boeve BF, et al. Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging. July 15, 2014 [Epub ahead of print].
69. Fujishiro H, Iseki E, Kasanuki K, et al. A follow up study of non-demented patients with primary visual cortical hypometabolism: prodromal dementia with Lewy bodies. J Neurol Sci. 2013;334:48-54.
70. Jacova C, Hsiung GY, Tawankanjanachot I, et al. Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology. 2013;81:1322-1331.
71. Lowe VJ, Weigand SD, Senjem ML, et al. Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology. 2014;82:1959-1967.
72. Rowe CC, Bourgeat P, Ellis KA, et al. Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol. 2013;74:905-913.
73. Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80:1784-1791.
74. Shaffer JL, Petrella JR, Sheldon FC, et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology. 2013;266:583-591.
75. Zhang D, Shen D. Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease. Neuroimage. 2012;59:895-907.
76. Gross AL, Manly JJ, Pa J, et al. Cortical signatures of cognition and their relationship to Alzheimer's disease. Brain Imaging Behav. 2012;6:584-598.
77. Westman E, Muehlboeck JS, Simmons A. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. Neuroimage. 2012;62:229-238.
78. Nettiksimmons J, Harvey D, Brewer J, et al. Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol Aging. 2010;31:1419-1428.
79. Johnson NA, Jahng GH, Weiner MW, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spinlabeling MR imaging: initial experience. Radiology. 2005;234:851-859.
80. Hu WT, Wang Z, Lee VM, Trojanowski JQ, Detre JA, Grossman M. Distinct cerebral perfusion patterns in FTLD and AD. Neurology. 2010;75:881-888.
81. Celone KA, Calhoun VD, Dickerson BC, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci. 2006;26:10222-10231.
82. Thomas JB, Brier MR, Bateman RJ, et al. Functional connectivity in autosomal dominant and late-onset Alzheimer disease. JAMA Neurol. 2014;71:1111-1122.
83. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain. 2011;134:1089-1100.
84. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631-639.
85. Kreisl WC, Lyoo CH, McGwier M, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain. 2013; 136:2228-2238.